LY3537021

LY3537021 is an investigational drug developed by Eli Lilly for the treatment of type 2 diabetes. It is a small molecule or peptide/protein drug that acts as an agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), also known as the gastric inhibitory polypeptide receptor. The mechanism of action involves stimulating GIPR to enhance insulin secretion in response to glucose, which may help improve glycemic control in patients with type 2 diabetes. The drug is administered via subcutaneous injection and is currently in Phase 1 clinical trials, including studies evaluating its safety both alone and in combination with GLP-1 receptor agonists[1][3][5][7].